Cheniere Energy, Inc. (AMEX) stock gained 2.73% to $13.94.
The company, on July 17 2012, announced the pricing of its previously announced
offering of its common stock at a price per share of $14.05. The size of the
offering has been upsized from 20 million shares to 28 million shares. The
offering is expected to close and settle on July 20, 2012. The Company intends
to use the net proceeds from the offering to repay the $204.6 million principal
amount outstanding of the 2.25% convertible notes due August 1, 2012, for
capital expenditures on the Creole Trail Pipeline and for general corporate
purposes.
Get Free Trend
Analysis on LNG
Triangle Petroleum Corporation (AMEX:TPLM) stock increased
4.11% to $5.82. The 52 week trading range for the company is $3.00 - $8.26.
Canaccord Genuity reiterated a 'Buy' on Triangle Petroleum with a price target
of $11.00 (from $9.00) on July 6, 2012.
Should Investors Buy
TMLP at CMP, Get
Free Report
Medgenics Inc (AMEX:MDGN) stock declined 11.91% to $13.46.
On July 17, 2012, Medgenics, Inc. (nyse mkt:MDGN and AIM)(nyse mkt:MEDG),
announces the launch of its Phase IIa clinical trial in Israel of EPODURE(TM)
Biopumps to treat anemia in patients with end-stage renal disease
("ESRD" or "kidney failure") on dialysis, through the
sustained delivery of erythropoietin ("EPO"). Following the Israeli
Ministry of Health's recent approval of the trial, Medgenics has enrolled and
begun to treat the first two dialysis patients ever to receive EPODURE
Biopumps.
Can MDGN rebound
After Today’s Fall Get Trend
Analysis
Rentech, Inc. (AMEX:RTK) shares fell 3.26% to $2.08. The 52
week trading range for the company is $0.72 - $2.40. The company is slated to
hold its 2012 second quarter conference call on Friday, August 10, 2012 at
12:00 p.m. PDT, during which time Rentech's senior management will review the
Company's financial results for the period and provide an update on corporate
developments.
Get Free Trend
Analysis on RTK
Hemispherx BioPharma, Inc (AMEX:HEB) shares increased 0.32%
to $0.405 after the company announced that it has submitted a new drug
application to ANMAT (Administracion Nacional de Medicamentos, Alimentos y
Tecnologia Medica), the agency responsible for the national regulation of
drugs, foods and medical technology in Argentina, under the ANMAT's Orphan Drug
regulations.
No comments:
Post a Comment